All patients with vaible tumor included (n=60)

Table 1: Patient Characteristics

Num. of
patients with
Factor data Statistics
Demographic and Clinical
Age 60 59.0 [54.0, 64.5]
Male 60 45 (75.0)
HCV 60 43 (71.7)
Alive 60 59 (98.3)
Any LRT 60 35 (58.3)
No. of adjuvant txs prior to OLT 60
0 25 (41.7)
1 19 (31.7)
2-3 16 (26.7)
Platelets prior to OLT (x 109/L) 60 72.5 [51.5, 110.0]
Diagnosis
Size of largest tumor 54 2.6 [1.9, 3.9]
Total tumor diameter 34 3.2 [2.3, 6.2]
Within Milan Dx 55 42 (76.4)
Location 51
Left 11 (21.6)
Right 32 (62.8)
Bilobular 8 (15.7)
Num. Tumors Dx 55
1 31 (56.4)
2 15 (27.3)
3+ 9 (16.4)
Last Radiology before Tx
Size of largest tumor 30 2.7 [1.8, 3.5]
Total tumor diameter 29 3.5 [2.1, 4.5]
Within Milan 32 27 (84.4)
Num. Tumors 31
1 18 (58.1)
2 9 (29.0)
3+ 4 (12.9)
Explant
Largest lesion on explant path 60 3.0 [2.2, 4.1]
Vascular Invasion 60 16 (26.7)
Differentiation 60
Well 10 (16.7)
Moderately 43 (71.7)
Poorly 7 (11.7)
Within Milan 60 36 (60.0)
Necrosis 60 39 (65.0)
Num. Tumors 60
1 25 (41.7)
2 12 (20.0)
3+ 23 (38.3)
Pre-OLT Markers
Pre-OLT AFP 60 12.5 [6.2, 93.5]
VEGF 57 34.0 [30.9, 50.0]
PIVKA 37 13.8 [3.6, 32.4]
AFP-L3 ≥ 10 37 29 (78.4)
Post-OLT Markers
AFP 44 4.1 [3.1, 6.6]
VEGF 38 49.6 [36.2, 65.0]
PIVKA 38 2.5 [2.0, 7.5]
AFP-L3 ≥ 10 37 37 (100.0)
Post-Pre OLT Levels
AFP 44 -7.2 [-73.8, -2.5]
VEGF 38 5.2 [-7.0, 22.5]
PIVKA 19 -1.5 [-12.8, 1.1]
Follow-up
Months diagnosis to OLT 58 4.7 [2.3, 7.3]
Months Last LRT to OLT 36 2.4 [1.0, 4.2]
Post-OLT Follow-up (yrs) 60 8.0 [2.3, 16.0]
Values presented as N (%) or Median [P25, P75]
Table 2: Pre-OLT Markers and Histological Characteristics
AFP-L3%
VEGF AFP PIVKA
Histologic features ≥ 10
Vascular invasion 40.3 [30.9, 61.5] 19.8 [8.2, 52.5] 10.3 [6.1, 46.9] 5 (17.2)
No vascular invasion 34.0 [30.9, 49.3] 12.1 [6.1, 117.6] 14.4 [2.6, 28.6] 24 (82.8)
p-value 0.48 0.73 0.29 0.33

Within Milan 34.0 [30.9, 49.3] 8.7 [5.9, 75.6] 7.7 [3.6, 28.6] 19 (65.5)
Beyond Milan 42.3 [30.9, 80.5] 30.4 [9.5, 96.4] 20.4 [2.8, 41.2] 10 (34.5)
p-value 0.22 0.24 0.42 0.99

Poor Differentiation 75.0 [30.9, 138.0] 51.2 [11.9, 201.2] 4.0 [1.9, 6.1] 0 (0.0)
Well/Moderate Differentiation 34.0 [30.9, 49.3] 11.6 [6.1, 92.5] 14.9 [3.6, 35.3] 29 (100.0)
p-value 0.33 0.22 0.19 0.007

HCV 34.0 [30.9, 49.5] 14.6 [6.4, 100.3] 14.4 [2.4, 30.5] 22 (75.9)
No HCV 35.2 [30.9, 60.0] 8.6 [6.1, 53.9] 10.3 [6.1, 35.3] 7 (24.1)
p-value 0.73 0.33 0.63 0.99

Locoregional therapy 42.3 [30.9, 64.0] 32.4 [8.9, 181.2] 15.4 [3.2, 33.8] 18 (62.1)
No locoregional therapy 30.9 [30.9, 48.0] 6.9 [5.7, 53.9] 7.7 [3.9, 28.6] 11 (37.9)
p-value 0.083 0.03 0.97 0.69

Multiple tumors 37.5 [30.9, 53.0] 12.6 [6.8, 140.7] 15.8 [2.6, 40.9] 18 (62.1)
1 tumor 30.9 [30.9, 49.5] 11.6 [5.7, 56.6] 6.6 [3.9, 28.6] 11 (37.9)
p-value 0.13 0.39 0.5 0.69
VEGF, AFP and PIVKA presented as Median [P25, P75] with p-values corresponding to Wilcoxon ranks sum tests
AFP-L3% presented as N (%) with p-values corresponding to Fisher's Exact tests
AFP-L3% Compared to subjects who did not receive LRT, those who did
< 10 had significantly higher AFP levels prior to OLT. In addition,
subjects with poor tumor differentiation were more likely ot have
3 (37.5) AFP-L3 lower than 10%.
5 (62.5)
0.33

5 (62.5)
3 (37.5)
0.99

3 (37.5)
5 (62.5)
0.007

6 (75.0)
2 (25.0)
0.99

6 (75.0)
2 (25.0)
0.69

4 (50.0)
4 (50.0)
0.69
 RT, those who did
OLT. In addition,
re more likely ot have
Vascular Invasion and Patient Characteristics

No Vascular
Vascular Invasion Invasion
Factor (N=16) (n=44) p-value
Domgraphic and Clinical
Age 57.5 [54.0, 62.5] 59.5 [55.0, 65.5] 0.53
Gender 0.99F
Female 4 (26.7) 11 (73.3)
Male 12 (26.7) 33 (73.3)
HCV 0.35F
No 6 (35.3) 11 (64.7)
Yes 10 (23.3) 33 (76.7)
Alive† 0.99F
No 0 (0.0) 1 (100.0)
Yes 16 (27.1) 43 (72.9)
Any LRT 0.84
No 7 (28.0) 18 (72.0)
Yes 9 (25.7) 26 (74.3)
No. of adjuvant txs prior to OLT 0.62
0 7 (28.0) 18 (72.0)
1 3 (15.8) 16 (84.2)
2-3 6 (37.5) 10 (62.5)
Platelets prior to OLT (x 109/L) 81.5 [45.0, 140.5] 71.0 [53.0, 103.5] 0.84
Diagnosis
Size of largest tumor† 3.0 [2.0, 4.0] 2.4 [1.7, 3.6] 0.14
Total tumor diameter† 4.8 [3.0, 8.5] 2.9 [2.3, 4.1] 0.072
Milan Dx† 0.28F
Beyond 5 (38.5) 8 (61.5)
Within 9 (21.4) 33 (78.6)
Location† 0.67F
Bilobular 3 (37.5) 5 (62.5)
Unilobular 11 (25.6) 32 (74.4)
Num. Tumors Dx† 0.046
1 4 (12.9) 27 (87.1)
2 8 (53.3) 7 (46.7)
3+ 3 (33.3) 6 (66.7)
Last Radiology before Tx
Size of largest tumor† 3.0 [2.0, 3.8] 2.6 [1.3, 3.5] 0.44
Total tumor diameter† 3.7 [2.4, 5.0] 3.3 [2.1, 4.4] 0.42
MilanLast Rad† 0.99F
Beyond 2 (40.0) 3 (60.0)
Within 10 (37.0) 17 (63.0)
Num. Tumors† 0.95
1 8 (44.4) 10 (55.6)
 2 3 (33.3) 6 (66.7)
3+ 2 (50.0) 2 (50.0)
Explant
Largest lesion on explant path 4.0 [2.8, 5.4] 2.5 [2.1, 3.7] 0.018
Differentiation† 0.067F
Well 0 (0.0) 10 (100.0)
Moderately 13 (30.2) 30 (69.8)
Poorly 3 (42.9) 4 (57.1)
Milan Path 0.032
Beyond 10 (41.7) 14 (58.3)
Within 6 (16.7) 30 (83.3)
Necrosis 0.81
No 6 (28.6) 15 (71.4)
Yes 10 (25.6) 29 (74.4)
Num. Tumors 0.073
1 5 (20.0) 20 (80.0)
2 1 (8.3) 11 (91.7)
3+ 10 (43.5) 13 (56.5)
Pre-OLT Markers
Pre-OLT AFP 19.8 [8.2, 52.5] 12.1 [6.1, 117.6] 0.73
VEGF 40.3 [30.9, 61.5] 34.0 [30.9, 49.3] 0.48
PIVKA† 10.3 [6.1, 46.9] 14.4 [2.6, 28.6] 0.29
AFP-L3 ≥ 10† 0.33F
No 3 (37.5) 5 (62.5)
Yes 5 (17.2) 24 (82.8)
Post-OLT Markers
AFP† 4.5 [3.0, 7.0] 4.0 [3.1, 6.6] 0.99
VEGF† 53.0 [37.9, 60.0] 48.6 [36.2, 70.8] 0.71
PIVKA† 2.2 [2.0, 5.7] 2.6 [2.0, 8.1] 0.79
AFP-L3 ≥ 10† ----
No 0 (0.0) 0 (0.0)
Yes 12 (32.4) 25 (67.6)
Post-Pre OLT Levels
AFP† -15.0 [-49.5, -2.2] -6.7 [-85.2, -2.5] 0.97
VEGF† 0.0 [-3.0, 18.5] 5.3 [-9.5, 26.4] 0.68
PIVKA† -21.6 [-98.2, 327.3] -1.3 [-10.8, 1.1] 0.31
Follow-up
Months diagnosis to OLT† 4.6 [3.4, 10.4] 4.7 [2.0, 7.3] 0.63
Months Last LRT to OLT† 1.4 [0.6, 2.4] 3.3 [1.1, 5.2] 0.14
Post-OLT Follow-up (months) 13.6 [7.7, 17.7] 5.1 [1.7, 13.6] 0.04
Values presented as N (%) or Median (P25, P75)

p-values correspond to Wilcoxon rank sum tests for continuous variables, Mantel-
Haenszel chi-square tests for num. adjuvant treatments and num. of tumors,
Fisher's exact tests if denoted by F and Pearson's chi-square tests eotherwise.
†Data not available for all subjects
Pre-OLT VEGF was not found to be significantly associated with
vascular invasion (p = 0.71). In addition, area under the
Reciever Operating Characteristics (ROC) curve was 0.44 (95%
CI: 0.28, 0.60) which is not significantly different from chance
assignment.